Uric acid, an antioxidant found in high concentrations in serum and in the brain, has been hypothesized to protect against oxidative damage and cell death in Parkinson's disease. The authors tested this hypothesis among men participating in a 30-year prospective study known as the Honolulu Heart Program. Serum uric acid was measured in 7,968 men at the baseline examination held from 1965 to 1968. Of these men, 92 subsequently developed idiopathic Parkinson's disease (IPD). In analyses adjusted for age and smoking, men with uric acid concentrations above the median at enrollment had a 40% reduction in IPD incidence (rate ratio (RR) = 0.6; 95% confidence interval (Cl) 0.4-1.0). Reduced IPD incidence rates persisted in analyses restricted to nonsmokers (RR = 0.5; 95% Cl 0.3-1.0) and cases younger than age 75 years (RR = 0.5; 95% Cl 0.3-0.9). Incidence rates were not notably affected when analyses were restricted to cases that occurred more than 5 years after uric acid measurement (RR = 0.6; 95% Cl 0.4-1.0). Inclusion of known or computed correlates of uric acid in regression models did not substantially change risk of IPD. This study provides prospective evidence of an association between uric acid and reduced occurrence of IPD and indicates that further investigations of this association are warranted. Am J Epidemiol 1996; 144:480-4.
In 1981, Ames et al. (1) hypothesized that uric acid might protect against widespread cellular damage caused by free radicals generated through oxidative reactions, including protection from neurologic diseases. Subsequent serologic and autopsy studies supported the possibility that the antioxidant effect of uric acid, present in the serum and cellular fluids, might protect against idiopathic Parkinson's disease (IPD) (2, 3) .
In this report, we describe a prospective study of serum uric acid and IPD among 8,006 men in the Honolulu Heart Program cohort. Serum uric acid was measured at the baseline examination held from 1965 to 1968 and again in [1971] [1972] [1973] [1974] [1975] . In the ensuing 30 years, 92 men have developed IPD.
MATERIALS AND METHODS

Study population
Subjects were men who participated in the Honolulu Heart Program. At 1965 enrollment, all male Oahu residents of Japanese or Okinawan ancestry were eligible if listed in Selective Service records and if they had been born between 1900 and 1919. Approximately 70 percent of all eligible men were enrolled. The mean age of the men at the 1965-1968 baseline examination was 54 years (range, 45-68 years). Additional details about cohort characteristics and recruitment procedures have been published (4) . The 7,968 men (99.5 percent of 8,006 men) who had serum uric acid measurements obtained at the baseline examination form the basis of this report.
Exposure measurements
Serum uric acid was measured at the baseline examination (1965) (1966) (1967) (1968) and at the third cohort rescreening examination (1971) (1972) (1973) (1974) (1975) as previously described (5). For some analyses, men were dichotomized about the median uric acid concentrations (5.9 and 6.2 mg/100 ml at the first and third examinations, respectively). In other analyses, subjects were grouped into quartiles by using dividing points of 5.0, 5.8, and 6.8 mg/100 ml for the first examination and 5.3, 6.2, and 7.2 mg/100 ml for the third examination. Evaluated exposures included body weight, blood pressure, forced expiratory volume, lifestyle exposures (alcohol and smoking), and the following serum or urine measurements: uric acid, total cholesterol, triglycerides, and glucose. Of these variables, only smoking had previously been found to be associated with IPD among Honolulu Heart Program subjects (6) . The strongest risk associations for smoking had occurred when smoking history was categorized by number of years of smoking, as used in this paper.
Case definition
Ninety-two incident IPD cases were diagnosed after the baseline examination, but before November 30, 1994. Case identification methodology has been described previously (6) . Only cases confirmed by neurologists or by a neurosurgeon practicing neurology in Hawaii were accepted. Other possible and even probable cases were not accepted, which might favor inclusion of long-standing cases or cases in more healthconscious men. Briefly, cases were identified through four sources: 1) review of Oahu hospitalization records; 2) review of Hawaii death certificates; 3) review of medical records at the offices of eight of 10 Oahu neurologists; and 4) from a complete rescreening of the cohort (1991) (1992) (1993) (1994) . The rescreening included standardized questions about parkinsonism, an examination of signs and symptoms, and, for suspected cases, a comprehensive neurologic examination. Four cases who had Parkinson's disease at the baseline examination were excluded from the study.
Statistical analyses
Rate ratios were estimated using Cox's regression model for survival data analysis (7) . For most models, time-to-failure or time-to-censoring was calculated from the date of the uric acid measurement until the end of follow-up. In some analyses, time-to-failure or time-to-censoring was calculated from 5 years after the date of the uric acid measurement until the end of follow-up. In analyses with mortality as the outcome, follow-up time for cases was calculated beginning at the date of diagnosis of Parkinson's disease. Unless otherwise stated, the end of follow-up was the date of diagnosis, the date of death, or November 30, 1994, whichever came first. In some analyses, follow-up was limited to dates before age 75 years, in which case follow-up was either to date of diagnosis, the date of death, the last day before reaching age 75 years, or November 30, 1994, whichever came first. Honolulu Heart Program mortality data are complete through December 31, 1992, and incomplete between January 1, 1993 and November 30, 1994.
RESULTS
In preliminary analyses, we compared the baseline distributions of uric acid for men who subsequently developed IPD and for those who did not. The distribution for the future cases was shifted toward lower values, suggesting a possibly lower risk among men with the higher concentrations of serum uric acid (figure 1). To explore this possibility further, we evaluated the association between uric acid and IPD in multivariate, proportional hazard models, using the median cutoff (table 1) . On the basis of uric acid measurements from the first cohort examination, men with serum values above the median had a 40 percent reduced rate of IPD. These rate ratios were marginally significant in two-tailed testing. The corresponding rate reduction for the third cohort examination was 30 percent. Analysis by quartiles supports differing rates for men with above-average versus below-average uric acid levels (table 1) . However, none of the confidence intervals from the quartile analyses excluded 1.0. When uric acid was modeled as a continuous variable, statistically nonsignificant inverse associations were observed (table 1) .
Because of our Limited power to examine the shape of the associations using quartiles, in analyses restricted to cohort subgroups we chose the median categorization. In separate analyses for smokers and nonsmokers, a reduction in the age-and smokingadjusted rate ratio was greatest in nonsmokers (table  2) . Restriction of analyses to IPD cases that occurred at least 5 years after determination of serum uric acid had little effect on the rate ratio (table 2) . Similarly, a reduction in rate ratio associated with elevated serum uric acid was found in subjects with earlier IPD onset (before age 75 years) as well as later onset (table 2) . • Rate ratio (RR) and 95% confidence intervals (Cl) comparing men with serum uric acid concentrations above the median with men with uric acid concentrations equal to or below the median, t Follow-up was restricted to ages under 75 years. t Age-and smoking-adjusted. § Age-adjusted. II Follow-up was restricted to 5 or more years after the uric acid measurements.
In additional analyses, we examined a number of potential confounders in age-and smoking-adjusted multivariate analyses. Inclusion of the potential confounders did not greatly alter the strength of the association between uric acid and IPD (table 3) .
Finally, to determine whether a selective mortality related to serum uric acid levels might explain the results, we investigated the association between uric acid and mortality. After age adjustment, increased mortality was observed among men in the highest quartile of serum uric acid compared with the lower quartiles (table 4). Adjustment for risk factors for major chronic disease reduced the magnitude of this association (table 4) .
DISCUSSION
The results are consistent with the possibility that uric acid may protect against IPD. Since uric acid is a known antioxidant, proponents of the free radical theory of Parkinson's disease etiology had previously hypothesized such a protective effect (2, 3) . In this study, rates of incident IPD were lower in men with serum uric acid concentrations above the population median at two points in time separated by an approximate 6-year interval. These results could support either an etiologic role for uric acid or a role in delaying disease progression.
However, these findings must be interpreted with caution, as the associations between mediandichotomized uric acid values and IPD were only marginally significant. When uric acid was categorized into quartiles or modeled as a continuous variable, the associations were not statistically significant. The pattern using quartiles, however, did support a threshold effect, with rates increasing above the median.
A potential explanation of the apparent "high threshold effect" on protection from IPD is that of "selective mortality" (8) (9) (10) . Mortality also becomes an issue because IPD is difficult to diagnose: Early symptoms, such as confusion or slow gait, can be mistaken for aging or attributed to other diseases. As a consequence, it has been argued that IPD may be underdiagnosed among subjects who die of other dis- t Rate ratios (RR) and 95% confidence Intervals (Cl) comparing men with serum uric acid concentrations above the median at the first examination with men with uric add concentrations equal to or below the median.
* Rate ratio per standard deviation. Standard deviations were: for alcohol, 24.4 g; for systolic blood pressure, 21.0 mmHg; for diastollc Wood pressure, 11.7 mmHg; for serum glucose, 58.2 g/100 ml; for dietary protein, 35.6 g; for animal protein, 32.8 g; for physical activity Index, 45.3 units; and for weight, 21.1 pounds (9.58 kg). eases, especially if they die "early." (We believe it equally likely, however, that IPD is more frequently diagnosed in persons with potentially fatal chronic diseases because of the "medical detection/surveillance biases" associated with frequent physician visits and hospitalizations). Among Honolulu Heart Program cohort subjects, men in the highest quartile of serum uric acid not only had a reduced rate of IPD, but also had a 30 percent higher mortality rate than did men in the lowest quartile. This is in the direction that would be expected if selective mortality were operative. Some men with high uric acid levels and IPD may have died before their disease was diagnosed. The type of selective mortality often discussed is an increased mortality among smokers who develop Parkinson's disease. If a selective mortality bias exists, however, its magnitude might increase with age, since mortality increases with age and the combination of smoking and Parkinson's disease is hypothesized to accelerate death. Before IPD could be diagnosed, increasing proportions of cases might die from other smoking-related causes. However, when we restricted analyses to cases diagnosed before age 75 years (61 percent of all cases), the association between uric acid and IPD was as strong for the younger men as for the older men (table 2) . There are several other plausible explanations for the results. Previous analyses in the Honolulu Heart Program documented that uric acid is associated with a complex array of physiologic and lifestyle variables, including age and smoking, which are independent predictors of IPD occurrence (5) . When age and smoking were adjusted for, however, the association between uric acid and IPD "protection" persisted. The association was also most pronounced in "never smokers." This finding is intriguing in that smoking has been associated with an approximate halving of IPD risk (6, 9) . Conceivably, unknown beneficial effects of both smoking and uric acid might operate in only a subset of susceptible persons. Other variables associated with uric acid within the Honolulu Heart Program cohort include weight, alcohol intake, serum triglyc-erides, and glycosuria. When included in multivariate models, none of these variables were associated with substantial alteration of the rate ratio for uric acid.
A further possible bias is a diagnostic bias if men with high uric acid levels were selectively underdiagnosed. In the Honolulu Heart Program, however, uric acid is positively associated with education and management or skilled occupation (5) . As a consequence, men with high uric acid levels may be more likely to be diagnosed with early disease.
Another potential bias is "reverse causation bias" (9) . To examine this possibility, we excluded cases diagnosed within 5 years of the uric acid measurements. Such case subjects might have had early IPD symptoms or a presymptomatic state that led to an altered diet or physiologic state. However, the association between uric acid and IPD persisted even with this exclusion (table 2) .
Our attempts to explain the association between uric acid and IPD by study bias did not lead to an obvious explanation. Consequently, an alternative explanation-that uric acid may protect against IPD-also deserves consideration. The plausibility of this explanation is supported by circumstantial evidence that oxidative damage plays an etiologic role in IPD. Among several observations supporting this possibility are evidence in IPD patients of increased lipid peroxidation (11, 12) , increased levels of nonheme iron, which can accelerate oxidative reactions (13, 14) , and reduced levels of glutathione and glutathione peroxidase, which can limit the intracellular generation of free radicals (15, 16) . These observations suggest that patients with Parkinson's disease may be under sustained oxidative stress. The evidence for oxidative damage was considered sufficiently persuasive that vitamin E antioxidant therapy has been under investigation in clinical trials (17) , although it has been shown not to slow IPD progression (18) .
Support for the hypothesis that uric acid may protect against IPD is limited (12, (19) (20) (21) . Since uric acid is a water-soluble antioxidant that inactivates free radicals of oxygen and binds the main electron-transfer medium for free radical generation (iron), there is a theoretical basis for its involvement in decreasing oxidative damage through one or more mechanisms. In one study, uric acid was significantly lower in postmortem extracts of the parkinsonian versus normal substantia nigra (2) . In a second study, serum uric acid concentrations were lower in Parkinson's disease patients than in control subjects (3). Our results now add prospective evidence consistent with an association between uric acid and reduced IPD occurrence, suggesting a need for further study.
